Page S4 2) Experimental protocol for the synthesis of compounds 4-21.
1)
S2 2) Experimental protocol for the synthesis of compounds 4-21.
S4 3) Experimental protocols for drug sensitivity assays against T. b. brucei and HEK cells S24 4) Experimental protocols for Ubiquinol oxidase/TAO inhibitory assay S25 S2 T. b. brucei s427 (n ≥ 4) . b Resistance factor relative to WT without glycerol: RF = EC50 (in the presence of glycerol)/EC50 (without glycerol). c T. brucei strain from which all aquaporins were knocked out. d Resistance factor relative to WT. e T.
b. brucei strain resistant to pentamidine, diminazene, and melaminophenyl arsenicals. f Human embryonic kidney cells (n = 3). g Selectivity index (SI) = CC50/EC50 (T. brucei WT). h Not effective at 100 µM. i Not determined. j Salicylhydroxamic acid. k Pentamidine. l Diminazene. m Phenylarsine oxide.
General procedure C using 5a (14.8 mg, 0.033 mmol) and triphenylphosphine (9.8 mg, 0.037 mmol) in anhydrous acetonitrile (3 mL) . The reaction was stirred for 14 days. The product was isolated as orangish gummy solid (8.7 mg, 42%) by crystallization from CH2Cl2/hexano. HPLC (UV) 95%. 1 H NMR (400 MHz, CDCl3) δ 10.93 (s, 1H, OH), 16H, ArH), 6.42 (dd, J = 2.4, 4.6 Hz, 2H, ArH), 3.96 (t, J = 6.6 Hz, 2H, OCH2), 3.90 (s, 3H, OCH3), 3.98 -3.80 (m, 2H, CH2P), 1.77 (p, J = 6.9 Hz, 2H), 1.43 -1.19 (m, 22H) . 13 C NMR (75 MHz, CDCl3) δ 170. 6, 165.4, 163.8, 135.1, 133.9 (d, J = 10.0 Hz), 131.3, 130.6 (d, J = 12.4 Hz), 118.6 (d, J = 86.0 Hz), 108.0, 105.3, 101.3, 68.4, 52.1, 30.6 (d, J = 15.6 Hz), 29.7, 29.4, 29.3, 29.12, 26.07, 23.0 (d, J = 49.1 Hz), 22.8 (d, J = 4.5 Hz) . LRMS (ESI + ) m/z 626.2 (M+H) + .
(14-(3-Fluoro-4-(methoxycarbonyl)phenoxy)tetradecyl)triphenylphosphonium bromide (7b)
General procedure C using 5b (45.3 mg, 0.07 mmol) and triphenylphosphine (21.3 mg, 0.08 mmol) in anhydrous acetonitrile (1.5 mL) . The reaction was stirred for 5 days. The product was isolated as yellowish gummy solid (29.4 mg, 65%) by crystallization from CH2Cl2/hexane. HPLC (UV) > 95%. 1 H NMR (400 MHz, 10H, ArH), 6H, ArH), 6.67 (d, J = 8.9 Hz, 1H, ArH), 6.57 (d, J = 12.9 Hz, 1H, ArH), 3.95 (t, J = 6.6 Hz, 2H, OCH2), 3.85 (s, 3H, OCH3), 3.77 -3.71 (m, 2H, CH2P), 1.78 -1.71 (m, 2H), 1.60 -1.58 (m, 4H), 1.44 -1.38 (m, 2H), 1.36 -1.16 (m, 16H) . 13 5, 102.8 (d, J = 25.8 Hz), 68.8, 52.0, 30.5 (d, J = 15.6 Hz), 29.62, 29.57, 29.3, 29.0, 26.0, 22.9 (d, J = 49.7 Hz), 22.8 (d, J = 4.7 Hz) . HRMS (ESI + ) m/z 627.3404 (C40H49FO3P requires 627.3403).
(14-(4-(Methoxycarbonyl)-3-methylphenoxy)tetradecyl)triphenylphosphonium bromide (7c)
General procedure C using 5c (52.9 mg, 0.12 mmol) and triphenylphosphine (31.5 mg, 0.12 mmol) in anhydrous acetonitrile (2.5 mL) . The reaction was stirred for 11 days. The product was isolated as yellowish gummy solid (78.9 mg, ~100%) by crystallization from CH2Cl2/hexane. HPLC (UV) 95%. 1 H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.9 Hz, 1H, ArH), 7.82 -7.61 (m, 15H, ArH), 6.65 -6.61 (m, 2H, ArH), 3.88 (t, J = 6.5 Hz, 2H, OCH2), 3.74 (s, 3H, OCH3), 3.63 -3.55 (m, 2H, CH2P), 2.48 (s, 3H, ArCH3), 1.71 -1.64 (m, 2H), 1.61 -1.46 (m, 4H), 1.38 -1.31 (m, 2H), 1.24 -1.11 (m, 16H) . 13 C NMR (75 MHz, CDCl3) δ 167. 4, 161.8, 142.9, 135.0 (d, J = 3.2 Hz), 133.5 (d, J = 9.8 Hz), 132.8, 130.5 (d, J = 12.4 Hz), 121.2, 118.1 (d, J = 85.7 Hz), 117.3, 111.3, 67.9, 51.4, 30.9, 30.4 (d, J = 15.5 Hz), 29.4 (m), 29.2, 29.1, 29.0, 25.9, 22.7 (d, J = 50.2 Hz), 22.5 (d, J = 4.7 Hz), 22.2. HRMS (ESI + ) m/z 623.3663 (C41H52O3P requires 623.3654).
(14-(4-hydroxy-3-(methoxycarbonyl)phenoxy)tetradecyl)triphenylphosphonium bromide (7d)
General procedure C using 5d (32 mg, 0.07 mmol) and triphenylphosphine (22.7 mg, 0.086 mmol) in anhydrous acetonitrile (1 mL). The reaction was stirred for 3 days. The product was isolated as colorless solid (2.4 mg, 5%) by successive crystallizations from CH2Cl2/hexane/EtOAc and EtOAc. HPLC (UV) > 95%. 1 3, 155.5, 151.5, 135.5 (d, J = 3.1 Hz), 133.2 (d, J = 9.8 Hz), 130.7 (d, J = 12.5 Hz), 124.5, 118.2, 117.7 (d, J = 86.4 Hz), 113.0, 68.8, 52.2, 30.6 (d, J = 15.6 Hz), 29.6, 29.49, 29.46, 29.44, 29.43, 29.3 (d, J = 17.9 Hz), 29.2 (d, J = 5.2 Hz), 28.9, 25.9, 22.7 (d, J = 51.2 Hz), 22.5 (d, J = 4.6 Hz) . HRMS (ESI + ) m/z 625.3423 (C40H50O4P requires 625.3447).
(14-(4-(Ethoxycarbonyl)-3-hydroxy-5methylphenoxy)tetradecyl)triphenylphosphonium bromide (7e)
General procedure C using 5e (56.8 mg, 0.12 mmol) and triphenylphosphine (39.6 mg, 0.15 mmol) in anhydrous acetonitrile (2 mL). The reaction was stirred for 6 days. The product was isolated as colorless gummy solid (65.2 mg, 83%) by crystallization from CH2Cl2/hexane. HPLC (UV) 95%. 1 3, 105.0, 99.2, 67.9, 61.1, 30.4 (d, J = 15.3 Hz), 29.4 (m), 29.2, 29.1, 28.9, 25.8, 24.3, 22.7 (d, J = 49.9 Hz), 22.5 (d, J = 4.6 Hz), 14.2. HRMS (ESI + ) m/z 653.3779 (C42H54O4P requires 653.3760).
1-(14-(3-Fluoro-4-(methoxycarbonyl)phenoxy)tetradecyl)quinolin-1-ium (10b)
General procedure C using 5b (61.6 mg, 0.14 mmol) and quinoline (40.7 mg, 0.3 mmol) in anhydrous acetonitrile (2 mL). The reaction was stirred for 10 days. The product was isolated as colorless powder (24.6 mg, 36%) by successive crystallizations from CH2Cl2/hexane and CH3CN. HPLC (UV) 96%. 1 7, 147.2, 137.7, 136.0, 133.4 (d, J = 3.0 Hz), 131.2, 130.2, 130.1, 122.7, 118.4, 110.7 (d, J = 3.4 Hz), 102.7 (d, J = 25.8 Hz), 68. 8, 58.3, 52.1, 30.5, 29.62, 29.57, 29.52, 29.44, 29.35, 29.26, 29.0, 26.6, 26 .0. HRMS (ESI + ) m/z 494.3077 (C31H41FNO3 requires 494.3071).
1-(14-(4-(Methoxycarbonyl)-3-methylphenoxy)tetradecyl)quinolin-1-ium bromide (10c)
General procedure C using 5c (75 mg, 0.17 mmol) and quinoline (86.1 mg, 0.67 mmol) in anhydrous acetonitrile (2.5 mL). The reaction was stirred for 11 days. The product was isolated as brown solid (54.9 mg, 66%) by successive crystallizations from CH3CN and CH2Cl2/hexane. HPLC (UV) 95%. 1 H NMR (400 MHz, CDCl3) δ 10.34 (d, J = 5.4 Hz, 1H, ArH), 9.17 (d, J = 8.2 Hz, 1H, ArH), 8.37 (d, 2H, J = 7.6 Hz, ArH), 8.16 (dd, J = 6.9, 6.1 Hz, 2H, ArH), 7.91 (t, J = 7.6 Hz, 1H, ArH), 7.83 (d, 1H, J = 9.5 Hz, ArH), 6.78 -6.54 (m, 2H, ArH), 5.33 (t, J = 7.5 Hz, 2H, CH2N), 3.90 (t, J = 6.6 Hz, 2H, OCH2), 3.77 (s, 3H, OCH3), 2.51 (s, 3H, ArCH3), 2.03 (p, 2H, J = 7.6 Hz), 1.70 (p, 2H, J = 6.7 Hz), 1.45 -1.32 (m, 4H), 1.28 -1.15 (m, 16H). 13 C NMR (75 MHz, CDCl3) δ 167. 5, 161.9, 150.3, 147.4, 142.9, 137.6, 136.0, 132.9, 131.2, 130.1, 130.0, 122.6, 121.3, 118.3, 117.4, 111.3, 68.0, 58.2, 51.5, 30.4, 29.5 (m), 29.32, 29.29, 29.14, 29.08, 26.5, 25.9, 22.3 . HRMS (ESI + ) m/z 490.3320 (C32H44NO3 requires 490.3321).
1-(14-(4-(Ethoxycarbonyl)-3-hydroxy-5-methylphenoxy)tetradecyl)quinolin-1-ium bromide (10e)
General procedure C using 5e (174 mg, 0.37 mmol) and quinoline (58.3 mg, 0.45 mmol) in anhydrous acetonitrile (2 mL). The reaction was stirred for 10 days. The product was isolated as brownish solid (50.6 mg, 39%) by successive crystallizations from CH2Cl2/hexane and CH3CN. HPLC (UV) > 95%. 1 H NMR (400 MHz, CDCl3) δ 11.80 (s, 1H, OH), 10.47 (d, J = 5.7 Hz, 1H), 9.13 (d, J = 8.4 Hz, 1H), 8.36 (t, J = 7.5 Hz, 2H), 8.21 -8.16 (m, 2H), 7.94 (t, J = 7.6 Hz, 1H), 6.27 -6.24 (m, 2H), 5.38 (t, J = 7.6 Hz, 2H, CH2N), 4.35 (q, J = 7.1 Hz, 2H, CH3CH2O), 3.93 -3.89 (m, 2H, OCH2), 2.47 (s, 3H, ArCH3), 2.14 -1.99 (m, 2H), 1.85 -1.70 (m, 4H), 1.54 -1.42 (m, 2H), 1.38 (t, 3H, J = 7.0 Hz), 1.34 -1.18 (m, 16H). 13 C NMR (101 MHz, CDCl3) δ 171. 9, 165.6 (d), 163.5, 150.9, 147.1, 143.2 (d), 137.8, 136.0, 131.2, 130.2, 130.1, 122.8, 118.4, 111.6 (d), 105.2, 99.3 (d), 68.1, 61.3, 58.3, 34.2, 32.9, 30.5, 29.63, 29.61, 29.57, 29.52, 29.44, 29.40, 29.3, 29.1, 28.9, 28.3, 26.6, 26.0, 24.5, 14.3 . HRMS (ESI + ) m/z 520.3427 (C33H46NO4 requires 520.3427).
General procedure D. A Kimax tube was charged with a mixture of ester (0.02 mmol, 1 equiv.) and potassium carbonate powder (3 equiv.) in MeOH/H2O solution (5/1, v/v; 1.2 mL) . The reaction mixture was stopped with a screwcap and was stirred at 50 ºC for several days until complete hydrolysis. 0.1 N HCl (2 mL) and CH2Cl2 (3 mL) were added to the cooled reaction and the mixture was stirred at room temperature for a few minutes.
S12
The organic phase was separated, dried (Na2SO4) and evaporated to give the pure crude carboxylic acid.
(10-(4-carboxy-3-hydroxyphenoxy)decyl)triphenylphosphonium bromide (8a)
General procedure D using 6a (13 mg, 0.02 mmol) and K2CO3 (8 mg, 0.06 mmol). The reaction mixture was stirred at 50 ºC for 67 h. The product was isolated as colorless gummy solid after workup (12 mg, ~100%). HPLC (UV) > 95 %. 1 7, 29.1, 28.94, 28.88, 28.84, 28.78, 25.6, 22.4 (d, J = 46.9 Hz) . HRMS (ESI + ) m/z 555.2675 (C35H40O4P requires 555.2664).
(14-(4-carboxy-3-hydroxyphenoxy)tetradecyl)triphenylphosphonium bromide (9a)
General procedure D using 7a (7 mg, 0.01 mmol) and K2CO3 (5 mg, 0.033 mmol). The reaction mixture was stirred at 50 ºC for 3 days. The product was isolated as greyish gummy solid after workup (5.3 mg, 77%). HPLC (UV) > 95%. 1 8, 106.2, 101.1, 67.6, 30.6 (d, J = 15.7 Hz), 30.3, 29.6, 29.5 (d, J = 7.9 Hz), 29.4 (d, J = 12.0 Hz), 28. 9, 28.6, 28.5, 27.9, 26.9, 25.2, 23.3, 22.3 (d, J = 49.8 Hz) . HRMS (ESI + ) m/z 611.3296 (C39H48O4P requires 611.3290).
(14-(4-carboxy-3-fluorophenoxy)tetradecyl)triphenylphosphonium bromide (9b) S13 General procedure D using 7b (8 mg, 0.011 mmol) and K2CO3 (6.6 mg, 0.048 mmol). The reaction mixture was stirred at 50 ºC for 67 h. The product was isolated as colorless gummy solid after workup (8 mg, ~100%) . HPLC (UV) > 95%. 1 
(14-(4-carboxy-3-methylphenoxy)tetradecyl)triphenylphosphonium bromide (9c)
General procedure D using 7c (12 mg, 0.017 mmol) and K2CO3 (8 mg, 0.058 mmol). The reaction mixture was stirred at 50 ºC for 11 days. The product was isolated as colorless gummy solid after workup (5.4 mg, 46%) . HPLC (UV) > 95 %. 1 (14-(4-carboxy-3-hydroxy-5-methylphenoxy)tetradecyl)triphenylphosphonium bromide (9e) General procedure D using 7e (15.5 mg, 0.021 mmol), K2CO3 (8.8 mg, 0.063 mmol) and EtOH/H2O solution (5/1, v/v; 1.2 mL) . The reaction mixture was stirred at 50 ºC for 7 days. The product was isolated as brownish gummy solid after workup (15 mg, ~100%). HPLC (UV) > 95%. 1 7, 29.5, 29.43, 29.42, 29.3, 29.2, 29.0, 28.9, 25.8, 24.1, 22.6 (d, J = 4.8 Hz) , 22.5 (d, J = 50.5 Hz). HRMS (ESI + ) m/z 625.3430 (C40H50O4P requires 625.3447).
1-(14-(4-carboxy-3-methylphenoxy)tetradecyl)quinolin-1-ium bromide (11c)
A mixture of 10c (9.2 mg, 0.016 mmol) in 48% aqueous HBr was stirred at 65 ºC for 20 h. Then, AcOH (1 mL) was added to help dissolve the precipitate and the heating was resumed for 1.5 h. The crude reaction mixture was partitioned between CH2Cl2 and H2O. The aqueous phase was extracted with CH2Cl2. The combined organic extracts were washed with brine, dried (Na2SO4), and evaporated to give a crude brown solid containing 11c and brominated by-products. Recrystallization from CH3CN at 4 ºC yielded 11c as off-white solid (3.8 mg, 42%) . HPLC (UV) 95%. 1 H NMR (400 MHz, CDCl3+CD3OD) δ 10.11 (brs, 1H), 8.93 (brs, 1H), 8.34 -8.10 (m, 4H), 7.94 (dd, J = 10.1, 5.5 Hz, 2H), 6.73 -6.66 (m, 1H), 5.20 (brs, 2H), 3.96 (t, J = 6.4 Hz, 2H), 2.56 (s, 3H), 2.34 -1.99 (m, 8H), 1.74 (p, J = 6.8 Hz, 2H), 1.60 -1.10 (m, 14H). 13 C NMR (101 MHz, CDCl3) δ 169. 9, 162.2, 149.8, 148.0, 143.4, 138.1, 136.6, 133.6, 131.5, 130.7, 130.6, 122.8, 121.8, 118.4, 117.7, 111.6, 68.3, 59.0, 33.9, 30.6, 29.73, 29.69, 29.59, 29.45, 29.33, 29.28, 26.9, 26.1, 22.4 . HRMS (ESI + ) m/z 476.3169 (C31H42NO3 requires 476.3165).
Synthesis of TAO inhibitors with geranyl and farnesyl tail
Note: the geranyl and farnesyl derivatives obtained as oil should be stored at 4 ºC.
(2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl acetate (12) S15 A round-bottomed flask flushed with argon was charged with SeO2 (115 mg, 1.04 mmol), salicylic acid (454 mg, 3.29 mmol) and anhydrous CH2Cl2 (38 mL). t BuOOH (12 mL, 124 mmol) was added and the reaction mixture was stirred at room temperature for 30 min. Then, geranyl acetate (7 mL, 32.7 mmol) was added dropwise and the mixture was stirred at room temperature for 44 h. The solvent was removed under vacuum and the crude product was partitioned between EtOAc and 10% KOH. The organic phase was washed successively with 0.1 M HCl (1×) and brine (2×). The organic phase was dried (MgSO4) and the solvent was removed under vacuum to give a crude oil which was purified by chromatography using hexane/EtOAc (7:1). Yellowish oil (3.01 g, 43%). HPLC (UV) > 90%. 1 (2E,6E,10E)-12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl acetate (13) A round-bottomed flask flushed with argon was charged with SeO2 (106 mg, 0.95 mmol), salicylic acid (452 mg, 3.27 mmol) and anhydrous CH2Cl2 (55 mL). t BuOOH (11 mL, 114 mmol) was added and the reaction mixture was stirred at room temperature for 30 min. Then, farnesyl acetate (7 mL, 32.7 mmol) was added dropwise and the mixture was stirred at room temperature for 3 days. The solvent was removed under vacuum and the crude product was partitioned between EtOAc and 10% KOH. The organic phase was washed successively with 0.1 M HCl and brine (2×). The organic phase was dried (MgSO4) and the solvent was removed under vacuum to give a crude oil which was purified by silica chromatography using hexane/EtOAc (7:1) . Yellowish oil (4.38 g, 52%) . HPLC (UV) >80%. 1 (2E,6E)-8-bromo-3,7-dimethylocta-2,6-dien-1-yl acetate (14) To a cooled (ice-bath) solution of 12 (210 mg, 0.98 mmol) in anhydrous CH2Cl2 (3 mL) was added PPh3 (480 mg, 1.44 mmol) and CBr4 (427 mg, 1.29 mmol). The reaction mixture was stirred at 4 ºC for 1 day. The solvent was removed under vacuum and the crude product was dissolved in hexane. The solid precipitate was filtered off and the filtrate was evaporated under vacuum to give 14 as yellowish oil that was used without further purification (176 mg, 65%). HPLC (UV) >75%. 1 H NMR (300 MHz, CDCl3) δ 5.58 -5.54 (m, 1H), 5.36 -5.32 (m, 1H) (((2E,6E,10E)-12-acetoxy-2,6,10-trimethyldodeca-2,6,10-trien-1-yl) 
oxy)-2hydroxy-6-methylbenzoate (15e)
General procedure B using 12 (285 mg, 1.38 mmol) in anhydrous THF (0.5 mL) and a solution of 2e (324 mg, 1.66 mmol), PPh3 (435 mg, 1.67 mmol) and a solution of DIAD (359 mg, 1.78 mmol) in anhydrous THF (4 mL). The reaction mixture was stirred at room temperature for 4 h and the crude product was purified by silica chromatography using hexane/EtOAc (100:0 →25:1) to give 15e as colorless oil (169 mg, 27%). HPLC (UV) >95 %. 1 H NMR (400 MHz, CDCl3) δ 11.81 (s, OH), 2H, 2×ArH), 1H, C=CH), 1H, C=CH), 1H, C=CH), 4.58 (d, J = 7.1 Hz, 2H, CH2OAc), 4H, CH3CH2O, ArOCH2) , 2.49 (s, 3H, ArCH3), 2.18 -2.08 (m, 4H, 2×CH2CH=), 2.05 -1.98 (m, 7H, OAc, 2×CH2C=), 1.69 (s, 3H, CH3), 1.67 (s, 3H, CH3), 1.59 (s, 3H, CH3), 1.40 (t, J = 7.1 Hz, 3H, CH3CH2O). 13 C NMR (101 MHz, CDCl3) δ 171. 9, 171.2, 165.6, 163.3, 143.1, 142.3, 134.9, 130.4, 129.3, 124.2, 118.4, 111.8, 105.3, 99.7, 74.0, 61.5, 61.3, 39.6, 39.1, 26.4, 26.3, 24.5, 21.1, 16.6, 16.1, 14.4, 13.9 . LRMS (ESI + ) m/z 459.1 (M+H) + . HRMS (ESI + ) m/z 468.2668 (C27H38O6 requires 458.2668). (((2E,6E)-8-acetoxy-2,6-dimethylocta-2,6-dien-1-yl) 
Methyl

4-
oxy)-2hydroxybenzoate (17a)
General procedure A using 12 (81.6 mg, 0.38 mmol), 2a (77.5 mg, 0.46 mmol) and Ph3P (119.4 mg, 0.46 mmol) in anhydrous THF (4 mL), and a solution of DIAD (84 mg, 0.48 mmol) in anhydrous THF (0.9 mL). The reaction mixture was stirred 17 h at room temperature and the compound was purified by chromatography using hexane/EtOAc (100:0 → 30:1) to give 17a as colorless oil (68.3 mg, 49%). HPLC (UV) > 95%. 1 70 (s, 3H, CH3 ). 13 C NMR (101 MHz, CDCl3) δ 171. 2, 170.5, 165.0, 163.8, 141.6, 131.2, 130. 8, 128.7, 118.9, 108.2, 105.5, 101.7, 74.1, 61.4, 52.0, 39.0, 26.0, 21.1, 16.5, 13.9 . HRMS (ESI + ) m/z 362.1742 (C20H26O6 requires 362.1729). (((2E,6E)-8-acetoxy-2,6-dimethylocta-2,6-dien-1-yl) 
Methyl 4-
oxy)-2-fluorobenzoate (17b)
General procedure A using 12 (212 mg, 0.94 mmol), 2e (237 mg, 1.21 mmol), y Ph3P (338 mg, 1.29 mmol) in anhydrous THF (10 mL), and a solution of DIAD (243 mg, 1.2 mmol) in anhydrous THF (5.3 mL) . The reaction mixture was stirred 21 h at room temperature and the compound was purified by chromatography using hexane/EtOAc (100:0 → 25:1) to give 17e as colorless oil (195 mg, 52%). HPLC (UV) 100%. 1 13 C NMR (126 MHz, CDCl3) δ 171. 9, 171.3, 165.6, 163.3, 143.2, 141.8, 130.9, 128.6, 118.8, 111.9, 105.4, 99.7, 73.9, 61.5, 61.3, 39.0, 26.0, 24.6, 21.2, 16.6, 14.4, 14. 0. LRMS (ESI + ) m/z 413.2 (M+Na) + .
General procedure E. A Kimax tube was charged with a mixture of ester (0.05 mmol, 1 equiv.) and 1 M aqueous KOH (0.5 mL, 10 equiv.) in MeOH solution (0.5 mL). The reaction mixture was stopped with a screwcap and was stirred at 60 ºC until complete hydrolysis. The reaction was quenched with 1M aqueous HCl solution (0.6 mL) and partitioned between CH2Cl2 and water. The aqueous phase was further extracted with CH2Cl2 (1×) and the combined organic extracts were dried (Na2SO4) and evaporated to give the pure crude carboxylic acid. (((2E,6E,10E)-12-hydroxy-2,6,10-trimethyldodeca-2,6,10-trien-1yl) 
2-hydroxy-4-
oxy)-6-methylbenzoic acid (16e)
General procedure using 15e (36 mg, 0.079 mmol) and ethanol as solvent. The reaction mixture was stirred for 26 h at 60 ºC and quenched with 1M aqueous HCl solution. Compound 16e was isolated as yellowish gummy solid by crystallization from EtOAc (18 mg, 50%). HPLC (UV): 95%. 1 H NMR (400 MHz, CDCl3) δ 6.32 (s, 2H, ArH), 5.49 (t, J = 7.2, Hz, 1H, CHCH2OH), 5.41 (t, J = 7.0 Hz, 1H, =CHCH2), 5.10 (t, J = 6.7 Hz, 1H, =CHCH2), 4.39 (s, 2H, ArOCH2), 4.17 (d, J = 7. 0 Hz, 2H, CH2OH), 2.55 (s, 3H, ArCH3), 2.2 -1.9 (m, 8H, 2×CH2CH2), 1.70 (s, 3H, CH3), 1.67 (s, 3H, CH3), 1.59 (s, 3H, CH3) . 13 C NMR (75 MHz, CDCl3) δ 175. 5, 166.4, 164.2, 144.6, 140.2, 134.8, 130.2, 129.3, 124.5, 123.1, 112.2, 104.3, 99.8, 74.0, 59.6, 39.6, 39.1, 26.4, 26.3, 24.5, 16.4, 16.1, 14. 0. HRMS (ESI + ) m/z 388.2260 (C23H32O5 requires 388.2250). oil (12 mg, 98%). HPLC (UV) 100%. 1 H NMR (400 MHz, CDCl3) δ 10.96 (s, 1H, ArOH), 7.72 (d, J = 9.5 Hz, 1H, ArH), 2H, ArH), 1H, C=CH), 5.41 (td, 1H, J = 1.4, 7.0 Hz, C=CH), 4.41 (s, 2H, ArOCH2), 4.15 (d, J = 7.0 Hz, 2H, CH2OH) , 3.91 (s, 3H, OCH3), 2H, CH2CH2), 2.09 (t, J = 7.5 Hz, 2H, CH2CH2), 1.71 (s, 3H, CH3), 1.68 (s, 3H, CH3) . 13 C NMR (101 MHz, CDCl3) δ 170. 6, 165.1, 163.7, 139.0, 131.3, 130.7, 129.0, 124.1, 108.4, 105.5, 101.7, 74.2, 59.5, 52.1, 39.0, 26.0, 16.4, 14. 0. LRMS (ESI + ) m/z 321.25 (M+H) + . HRMS (ESI + ) m/z 320.1638 (C18H24O5 requires 320.1624). 4-(((2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dien-1 
Methyl
2-fluoro-
yl)oxy)benzoate (19b)
A mixture of 17b (15 mg, 0.041 mmol) and K2CO3 (6.4 mg, 0.045 mmol) in MeOH (2 mL) was stirred at room temperature for 2.5 h. The solvent was removed under vacuum and the crude product was partitioned between CH2Cl2 and water. The organic phase was washed with brine, dried (Na2SO4), and evaporated to give a crude oil. Silica chromatography using hexane/EtOAc: 100/0 → 80/20 yielded 19b as colorless powder (11 mg, 83%). 1 H NMR (400 MHz, CDCl3) δ 7.88 (t, J = 8.7 Hz, 1H), 6.72 (dd, J = 8.7, 2.5 Hz, 1H), 6.64 (dd, J = 12.8, 2.5 Hz, 1H), 5.52 (td, J = 6.3, 3.1 Hz, 1H), 1H) 6, 59.5, 52.1, 39.0, 26.1, 16.4, 14. 0. HRMS (ESI + ) m/z 322.1587 (C18H23FO4 requires 322.1580).
Methyl
4-(((2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dien-1-yl)oxy)-2methylbenzoate (19c)
A mixture of 17c (18 mg, 0.05 mmol) and K2CO3 (7.6 mg, 0.055 mmol) in MeOH (2 mL) was stirred at room temperature for 2.5 h. The solvent was removed under vacuum and the crude product was partitioned between EtOAc and water. The organic phase was washed with brine, dried (Na2SO4), and evaporated to give a crude oil. Silica chromatography using hexane/EtOAc: 100/0 → 80/20 yielded 19c as colorless powder (10 mg, 63%). 1 H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 8.2 Hz, 1H), 6.77 -6.71 (m, 2H), 5.58 -5.48 (m, 1H), 5.45 -5.35 (m, 1H) , 4.41 (s, 2H), 4.15 (d, J = 6.9 Hz, 2H), 3.85
3) Experimental protocols for drug sensitivity assays against T. b. brucei and HEK cells Test organisms and culture media
Three strains of bloodstream form (BSF) Trypanosoma brucei were used in this study to assess the trypanocidal activity of the new compounds: (i) A Wild type strain T. b. brucei Lister 427 (427-WT); 1 (ii) A multi-drug resistant strain, B48, which was created from 427-WT after deletion of the TbAT1 drug transporter 2 followed by adaptation to increasing concentrations of pentamidine; 3 (iii) A pentamidine-resistant aquaporin-null trypanosomes (aqp1-3 null), which was obtained by the knockout of all three aquaglyceroporin genes, hence were reported to display glycerol transport defects and respiratory-inhibitor sensitivity 4, 5 ; the aqp2 gene was specifically implicated in pentamidine-melarsoprol cross-resistance in field isolates of T. b. gambiense. 6, 7 All T. b. brucei strains were used only as bloodstream trypomastigotes and cultured in standard HMI-9 medium, supplemented with 10% heat inactivated fetal bovine serum (FBS), 14 μL of β-mercaptoethanol, and 3.0 g of sodium hydrogen carbonate per liter of medium (pH 7.4) . Parasites were cultured in vented flasks at 37 °C in a 5% CO2 atmosphere and were passaged every third day.
Drug sensitivity assays
The drug susceptibilities of trypanosomes were determined using the resazurin-based assay as previously described. 5, 8, 9 Briefly, the assays were performed in 96-well plates with 2 × 10 4 cells/well. This involves adjusting cell density to the required concentration of 2 × 10 5 cells/mL of which 100 μL was added to all of the wells in the plate having a 100 μl serially diluted test compound (200 μM top concentration) in HMI-9 medium + 10% Fetal Bovine Serum, then incubating trypanosomes and test compounds for a period of 48 hours at 37 °C and 5% CO2 before adding 20 µl filter-sterilized resazurin solution, which was prepared by adding 25 mg resazurin sodium salt to 200 mL PBS. This was followed by a further 24 h of incubation. Well-known trypanocides including pentamidine isethionate and diminazene aceturate (both from Sigma-Aldrich) were used as positive control. Fluorescence from the 96-well plates was measured using a FLUOstar Optima (BMG Labtech, Durham, NC, USA) set at wavelengths of 544 nm for excitation, 590 for emission, and a gain of 1250. EC50 values were calculated by non-linear regression using an equation for a sigmoidal dose-response curve with variable slope (GraphPad Prism 5.0, GraphPad Software Inc., San Diego, CA, USA).
Cytotoxicity assay using human embryonic kidney (HEK) 293-T cells
Toxicity of drugs to mammalian cells was carried out using Human Embryonic Kidney (HEK) Cells (strain 293T) according to a previously reported protocol. 5, 9 Briefly, HEK cells were grown in a culture containing 500 mL Dulbecco's Modified Eagle's Medium (DMEM) (Sigma), 50 mL New-born Calf Serum (NBCS) (Gibco), 5 mL Penicillin/Streptomycin (Gibco), and 5 mL L-Glutamine (200 mM, Gibco). The mammalian cells were incubated at 37 °C/5% CO2 and were passaged when they reached S25 80 -85% confluence in vented flasks. For the assay, cells were suspended at a density of 3 × 10 5 cells/mL, of which 100 µL was added to each well of a 96-well plate. The plate was incubated at 37 °C + 5% CO2 for 24 hours to allow cell adhesion to the plate. Serial drug dilutions were prepared in a separate 96-well sterile plate and 100 µL was transferred to the corresponding wells containing the cells; phenylarsine oxide (PAO) was used as positive control. The plate was then incubated at 37 °C /5% CO2 for an additional period of 30 h followed by the addition of 10 µL of resazurin solution (125 mg/L in PBS) and a final incubation at 37 °C /5% CO2 for 24 hours. The plate was read in a FLUOstar OPTIMA fluorimeter at wavelengths 530 nm for excitation and 590 nm for emission. GraphPad Prism 5.0 was used for analyzing the generated data, which was plotted to a sigmoid curve with variable slope to determine EC50 values. The selectivity index was calculated as EC50 (HEK)/EC50 (trypanosomes).
4) Experimental protocols for Ubiquinol oxidase/TAO inhibitory assay
Preparation of inner membrane-rich fraction, membrane solubilization, and purification of rTAO was performed exactly as described in our recent publication. 5 The purified rTAO was used for the TAO inhibitory assay. In this method, the absorbance changes of ubiquinol-1 at 278 nm were recorded on a JASCO V-630 spectrophotometer (JASCO corporation, Tokyo, Japan) over 2 minutes. Reactions were initiated by the addition of 150 µM ubiquinol-1 (ε278=15,000 M −1 cm −1 ) after 2 min of pre-incubation at 25 °C in the presence of 150 ng rTAO in a total reaction volume of 500 µL 50 mM Tris-HCl buffer (pH 7.4). To determine the IC50 values of test compounds, the reaction was initiated by the addition of a fixed concentration of ubiquinol-1 (150 µM), after 2 min pre-incubation (25 °C) in the presence of a fixed amounts of rTAO (150 ng) and varying concentrations of serially diluted test compounds, all in a 50 mM Tris-HCl (pH 7.4) buffer containing 0.05% (w/v) octaethylene glycol-monododecylether detergent. The data obtained were used to calculate the % inhibition of rTAO, which was plotted against the corresponding log of the test compound's concentration (M) to generate a sigmoidal curve. EC50 values were calculated by non-linear regression using an equation for a sigmoidal curve with variable slope (GraphPad Prism 6.0, GraphPad Software Inc., San Diego, CA, USA).
